Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended September 2024, Catalyst Pharmaceutical (CPRX) reported revenue of 0.57, compared to -122.97 million, representing a surprise of +4.65%. The company delivered an EPS surprise of +16.33%, with the consensus EPS estimate being $0.49.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...